stocks logo

HOOK

HOOKIPA Pharma Inc
$
0.893
0(0.000%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.890
Open
0.890
VWAP
0.89
Vol
1.94K
Mkt Cap
10.89M
Low
0.8807
Amount
1.72K
EV/EBITDA(TTM)
--
Total Shares
98.95M
EV
-29.38M
EV/OCF(TTM)
--
P/S(TTM)
1.20
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics based on its arenavirus platform. The Company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. Its two primary programs include HB-700 and Eseba-vec. HB-700 is a multi-KRAS mutant-targeting, investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Eseba-vec is an investigational immunotherapeutic agent in clinical development for the treatment of HPV16+ head and neck cancers. The Company has partnered with Gilead Sciences, Inc. to develop therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
3.38M
+149.26%
-0.690
-6.76%
3.38M
-28.24%
-0.660
-40%
3.38M
+161.63%
-0.640
-57.78%
Estimates Revision
The market is revising No Change the revenue expectations for HOOKIPA Pharma Inc. (HOOK) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -32.35%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-12.16%
In Past 3 Month
Stock Price
Go Down
down Image
-32.35%
In Past 3 Month
1 Analyst Rating
up Image
123.96% Upside
Wall Street analysts forecast HOOK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HOOK is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
up Image
123.96% Upside
Current: 0.893
sliders
Low
2.00
Averages
2.00
High
2.00
HC Wainwright & Co.
Arthur He
Strong Buy
to
Hold
Downgrades
n/a
2025-01-10
Reason
RBC Capital
Brian Abrahams
Buy
to
Hold
Downgrades
$48 → $2
2024-12-20
Reason
RBC Capital downgraded Hookipa Pharma to Sector Perform from Outperform with a price target of $2, down from $48. The company recently announced a restructuring, including an 80% workforce reduction and a pausing of clinical development for its lead program, eseba-vec for HPV16+ head and neck cancer, the analyst tells investors in a research note. RBC stills like the promise of Hook's programs and arenavirus platform technology in both oncology and infectious disease, and see potential for partnerships or a takeover at a higher valuation. However, such timing is challenging to predict, and with the company's strategic refocus now resetting the proprietary pipeline to preclinical stages, where it is difficult to ascribe meaningful value as of yet, the shares will trade near-term in the range of future cash levels, the analyst tells investors in a research note.
JMP Securities
Roy Buchanan
Buy
Maintains
$24 → $7
2024-11-21
Reason
JMP Securities lowered the firm's price target on Hookipa Pharma to $7 from $24 and keeps an Outperform rating on the shares. Hookipa announced Wednesday that it will reduce its workforce by about 80% starting this quarter and pause the eseba-vec cancer vaccine program in HPV16+ head-and-neck cancer, including an early termination of the Phase 1/2, not due to efficacy or safety, looking instead to partner the program, the analyst tells investors in a research note. The firm has removed eseba-vec from its valuation.
RBC Capital
Brian Abrahams
Buy
Maintains
$50 → $48
2024-11-15
Reason
JMP Securities
Roy Buchanan
Buy
Maintains
$23 → $24
2024-08-09
Reason

Valuation Metrics

The current forward P/E ratio for HOOKIPA Pharma Inc (HOOK.O) is -0.38, compared to its 5-year average forward P/E of -1.94. For a more detailed relative valuation and DCF analysis to assess HOOKIPA Pharma Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.94
Current PE
-0.38
Overvalued PE
-0.31
Undervalued PE
-3.57

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.07
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.73
Undervalued EV/EBITDA
-5.86

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
14.08
Current PS
1.22
Overvalued PS
30.41
Undervalued PS
-2.25

Financials

Annual
Quarterly
FY2025Q1
YoY :
-94.52%
2.00M
Total Revenue
FY2025Q1
YoY :
-219.89%
-17.51M
Operating Profit
FY2025Q1
YoY :
-207.26%
-15.43M
Net Income after Tax
FY2025Q1
YoY :
-207.89%
-1.23
EPS - Diluted
FY2025Q1
YoY :
-100.13%
32.00K
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
+265.51%
-565.37
FCF Margin - %
FY2025Q1
YoY :
-2058.80%
-769.81
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
39.4K
USD
2
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
105.0K
Volume
1
6-9
Months
182.9K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

HOOK News & Events

Events Timeline

2025-07-18 (ET)
2025-07-18
22:21:58
Hookipa Pharma to delist shares from Nasdaq
select
2025-01-30 (ET)
2025-01-30
06:15:27
Hookipa Pharma announces enrollment completion of Phase 1b HB-500 trial
select
2025-01-02 (ET)
2025-01-02
04:31:01
Hookipa Pharma to acquire Poolbeg Pharma
select
Sign Up For More Events

News

9.0
07-18SeekingAlpha
HOOKIPA Pharma to delist from Nasdaq and liquidate following Gilead asset sale
8.5
05-22SeekingAlpha
Gilead to buy certain Hookipa Pharma assets for up to $10M
4.0
03-03Business Insider
Hookipa Pharma (HOOK) Receives a Hold from RBC Capital
Sign Up For More News

FAQ

arrow icon

What is HOOKIPA Pharma Inc (HOOK) stock price today?

The current price of HOOK is 0.893 USD — it has increased 0 % in the last trading day.

arrow icon

What is HOOKIPA Pharma Inc (HOOK)'s business?

arrow icon

What is the price predicton of HOOK Stock?

arrow icon

What is HOOKIPA Pharma Inc (HOOK)'s revenue for the last quarter?

arrow icon

What is HOOKIPA Pharma Inc (HOOK)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for HOOKIPA Pharma Inc (HOOK)'s fundamentals?

arrow icon

How many employees does HOOKIPA Pharma Inc (HOOK). have?

arrow icon

What is HOOKIPA Pharma Inc (HOOK) market cap?